New Medication for Uncontrolled Eczema

Trial Objective

New Medication for Uncontrolled EczemaOur researchers are studying a new medication called dupilumab to determine how it affects the immune system, water loss in the skin, and the amount of bacteria in the skin of adults with atopic dermatitis (eczema).

People with chronic atopic dermatitis have dry, scaly, itchy skin and often have repeat viral and bacterial skin infections. A bacteria known as Staph aureus, or Staph, causes many of these infections. To control their symptoms, many people with atopic dermatitis use long-term topical or oral treatments. Long-term use of these medications can have side effects. For this reason, new treatments are being researched, especially for patients whose symptoms are not controlled by existing medications. The Food and Drug Administration recently approved dupilumab for moderate-to-severe atopic dermatitis.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have had chronic atopic dermatitis for at least three years, have it on more than 10 percent of their body, and have at least three active lesions that measure at least 4-by-4 centimeters on  their arms or legs may be eligible to participate. 

Age: 18-75    Gender: Any Gender


Estimated Time Commitment

10 visits and 1 telephone call over about 6-7 months



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Caroline Bronchick

Caroline Bronchick
303.398.1409

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More


*
*
*
*